SimB16: Modeling Induced Immune System Response against B16-Melanoma

Immunological therapy of progressive tumors requires not only activation and expansion of tumor specific cytotoxic T lymphocytes (CTLs), but also an efficient effector phase including migration of CTLs in the tumor tissue followed by conjugation and killing of target cells. We report the application of an agent-based model to recapitulate both the effect of a specific immunotherapy strategy against B16-melanoma in mice and the tumor progression in a generic tissue section. A comparison of the in silico results with the in vivo experiments shows excellent agreement. We therefore use the model to predict a critical role for CD137 expression on tumor vessel endothelium for successful therapy and other mechanistic aspects. Experimental results are fully compatible with the model predictions. The biologically oriented in silico model derived in this work will be used to predict treatment failure or success in other pre-clinical conditions eventually leading new promising in vivo experiments.

[1]  F. Hofstaedter,et al.  CD137 expression in tumor vessel walls. High correlation with malignant tumors. , 2001, American journal of clinical pathology.

[2]  Drew M. Pardoll,et al.  Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.

[3]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[4]  Lieping Chen,et al.  CD137 Is Expressed in Human Atherosclerosis and Promotes Development of Plaque Inflammation in Hypercholesterolemic Mice , 2008, Circulation.

[5]  Filippo Castiglione,et al.  Modelling vaccination schedules for a cancer immunoprevention vaccine , 2005, Immunome research.

[6]  Francesco Pappalardo,et al.  Genetic Algorithm Against Cancer , 2005, WILF.

[7]  Massimo Bernaschi,et al.  ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization , 2008, Briefings Bioinform..

[8]  Francesco Pappalardo,et al.  Modeling the competition between lung metastases and the immune system using agents , 2010, BMC Bioinformatics.

[9]  I. Melero,et al.  Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. , 2011, Cancer research.

[10]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[11]  Massimo Bernaschi,et al.  ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale† , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[12]  Filippo Castiglione,et al.  Vaccine protocols optimization: in silico experiences. , 2010, Biotechnology advances.

[13]  Francesco Pappalardo,et al.  A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY , 2010, Immunome research.

[14]  Francesco Pappalardo,et al.  Optimal vaccination schedules using simulated annealing , 2008, Bioinform..

[15]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[16]  Lieping Chen,et al.  Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ , 2010, Cancer Immunology, Immunotherapy.

[17]  Massimo Bernaschi,et al.  Modeling lymphocyte homing and encounters in lymph nodes , 2009, BMC Bioinformatics.

[18]  I. Melero,et al.  Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. , 2008, Trends in pharmacological sciences.

[19]  M. Colombo,et al.  Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. , 2006, Cancer research.

[20]  B. Sangro,et al.  Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? , 2009, Immunotherapy.

[21]  Massimo Bernaschi,et al.  Optimization of HAART with genetic algorithms and agent-based models of HIV infection , 2007, Bioinform..

[22]  Lieping Chen,et al.  Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. , 2002, Cancer research.

[23]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[24]  Lieping Chen,et al.  Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens , 2004, International journal of cancer.

[25]  Salvatore Musumeci,et al.  Modeling immune system control of atherogenesis , 2008, Bioinform..

[26]  F. Pappalardo,et al.  In silico modeling and in vivo efficacy of cancer-preventive vaccinations. , 2010, Cancer research.

[27]  Fumito Ito,et al.  Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines , 2004, Cancer Research.

[28]  Lieping Chen,et al.  Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination , 2009, Clinical Cancer Research.